Total Payments
$623,418
2024 Payments
$79,105
Companies
34
Transactions
416
Medicare Patients
1,002
Medicare Billing
$86,049
Payment Breakdown by Category
Consulting$247,151 (39.6%)
Other$201,451 (32.3%)
Travel$140,061 (22.5%)
Research$29,138 (4.7%)
Food & Beverage$5,610 (0.9%)
Education$7.08 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $247,151 | 70 | 39.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $195,566 | 140 | 31.4% |
| Travel and Lodging | $140,061 | 112 | 22.5% |
| Unspecified | $29,138 | 14 | 4.7% |
| Honoraria | $5,885 | 5 | 0.9% |
| Food and Beverage | $5,610 | 74 | 0.9% |
| Education | $7.08 | 1 | 0.0% |
Payments by Type
General
$594,280
402 transactions
Research
$29,138
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim International GmbH | $161,814 | 117 | $0 (2024) |
| Novo Nordisk AS | $96,537 | 40 | $0 (2024) |
| AstraZeneca AB | $79,237 | 26 | $0 (2022) |
| AstraZeneca UK Limited | $68,435 | 55 | $0 (2024) |
| Novo Nordisk Inc | $31,637 | 19 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $25,612 | 32 | $0 (2024) |
| PFIZER INC. | $21,015 | 13 | $0 (2024) |
| Nippon Boehringer Ingelheim Co., Ltd. | $19,222 | 6 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $17,455 | 15 | $0 (2017) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $15,647 | 22 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $79,105 | 49 | Boehringer Ingelheim International GmbH ($29,449) |
| 2023 | $28,939 | 20 | PFIZER INC. ($10,930) |
| 2022 | $108,101 | 32 | AstraZeneca AB ($49,750) |
| 2021 | $60,136 | 41 | Novo Nordisk AS ($13,345) |
| 2020 | $61,149 | 44 | Boehringer Ingelheim International GmbH ($24,929) |
| 2019 | $106,818 | 69 | Novo Nordisk AS ($44,921) |
| 2018 | $87,114 | 73 | Boehringer Ingelheim International GmbH ($25,776) |
| 2017 | $92,056 | 88 | Boehringer Ingelheim International GmbH ($33,655) |
All Payment Transactions
416 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/28/2024 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| 11/28/2024 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,870.00 | General |
| 11/28/2024 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $483.44 | General |
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $5,370.00 | General |
| 10/21/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $6,281.25 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 10/21/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | In-kind items and services | $5,773.03 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 10/21/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | In-kind items and services | $831.56 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 10/21/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | In-kind items and services | $611.18 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 10/21/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | In-kind items and services | $343.94 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 10/18/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $805.50 | General |
| 10/08/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,575.00 | General |
| 09/30/2024 | Boehringer Ingelheim International GmbH | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,064.70 | General |
| Category: DIABETES | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $805.50 | General |
| 09/11/2024 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $863.92 | General |
| 09/10/2024 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $76.36 | General |
| 07/23/2024 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,790.11 | General |
| 06/30/2024 | Boehringer Ingelheim International GmbH | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $3,219.80 | General |
| Category: DIABETES | ||||||
| 06/30/2024 | Boehringer Ingelheim International GmbH | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,064.70 | General |
| Category: DIABETES | ||||||
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $723.31 | General |
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $501.05 | General |
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $501.05 | General |
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $167.50 | General |
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $167.50 | General |
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $104.69 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EX9924-4473 | Novo Nordisk AS | $25,188 | 10 |
| ERTUGLIFLOZIN CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,950 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 178 | 197 | $74,445 | $15,026 |
| 2022 | 6 | 233 | 308 | $100,055 | $20,214 |
| 2021 | 8 | 294 | 376 | $117,935 | $25,781 |
| 2020 | 7 | 297 | 402 | $125,110 | $25,028 |
Total Patients
1,002
Total Services
1,283
Medicare Billing
$86,049
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 127 | 138 | $51,750 | $9,872 | 19.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 33 | 38 | $18,810 | $4,542 | 24.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Facility | 2023 | 18 | 21 | $3,885 | $612.15 | 15.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 129 | 149 | $55,875 | $10,834 | 19.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 38 | 45 | $22,275 | $4,959 | 22.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 33 | $8,250 | $1,773 | 21.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 20 | 42 | $5,880 | $1,313 | 22.3% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Facility | 2022 | 19 | 27 | $4,715 | $712.26 | 15.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 12 | $3,060 | $623.00 | 20.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 126 | 132 | $49,500 | $10,176 | 20.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 51 | 56 | $27,720 | $6,586 | 23.8% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 38 | 99 | $13,860 | $3,233 | 23.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 14 | 14 | $8,050 | $1,638 | 20.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 25 | 26 | $6,630 | $1,492 | 22.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 13 | 22 | $5,500 | $1,285 | 23.4% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 12 | 12 | $4,200 | $945.45 | 22.5% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Facility | 2021 | 15 | 15 | $2,475 | $424.76 | 17.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 135 | 150 | $56,250 | $9,061 | 16.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 60 | 64 | $13,955 | $3,976 | 28.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 31 | 34 | $16,830 | $3,206 | 19.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 21 | 85 | $11,900 | $2,864 | 24.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 21 | 21 | $12,075 | $2,361 | 19.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 20 | $7,100 | $1,805 | 25.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 17 | 28 | $7,000 | $1,756 | 25.1% |
About Dr. Silvio Inzucchi, MD
Dr. Silvio Inzucchi, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1073598538.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Silvio Inzucchi, MD has received a total of $623,418 in payments from pharmaceutical and medical device companies, with $79,105 received in 2024. These payments were reported across 416 transactions from 34 companies. The most common payment nature is "Consulting Fee" ($247,151).
As a Medicare-enrolled provider, Inzucchi has provided services to 1,002 Medicare beneficiaries, totaling 1,283 services with total Medicare billing of $86,049. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location New Haven, CT
- Active Since 12/07/2005
- Last Updated 07/21/2008
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1073598538
Products in Payments
- JARDIANCE (Drug) $172,003
- FARXIGA (Drug) $136,740
- Rybelsus (Drug) $18,898
- SOLIQUA (Drug) $17,448
- SOTAGLIFLOZIN (Drug) $10,292
- RYBELSUS (Drug) $6,290
- INVOKANA (Drug) $6,054
- STEGLATRO (Drug) $3,992
- Ozempic (Drug) $3,540
- Triage (Device) $2,500
- Actosmet (Drug) $2,000
- Belviq (Drug) $2,000
- EMPAGLIFLOZIN (Drug) $2,000
- NEXLETOL (Drug) $1,816
- DS8500 (Drug) $1,800
- ALERE AFINION HBA1C CONTROL (Device) $1,148
- NEXLIZET (Drug) $305.25
- Afinion 2 (Device) $300.00
- Strensiq (Drug) $152.32
- Minimed 630G (Device) $100.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in New Haven
Philip Goldberg, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $428,337
Endocrinology, Diabetes & Metabolism $428,337
Gerald Shulman, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $345,726
Endocrinology, Diabetes & Metabolism $345,726
Kevan Herold, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $170,878
Endocrinology, Diabetes & Metabolism $170,878
Karl Insogna, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $58,938
Endocrinology, Diabetes & Metabolism $58,938
Dr. Adam Mayerson, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $27,516
Endocrinology, Diabetes & Metabolism $27,516
Dr. Clemens Bergwitz, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $27,377
Endocrinology, Diabetes & Metabolism $27,377